Analysts predict that Abeona Therapeutics Inc (NASDAQ:ABEO) will post earnings of ($0.16) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Abeona Therapeutics’ earnings, with estimates ranging from ($0.20) to ($0.05). Abeona Therapeutics posted earnings of ($0.21) per share during the same quarter last year, which would suggest a positive year over year growth rate of 23.8%. The firm is expected to report its next quarterly earnings results on Tuesday, August 21st.
On average, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.34). For the next financial year, analysts forecast that the company will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.98) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $0.27 million. Abeona Therapeutics had a negative net margin of 939.83% and a negative return on equity of 23.57%.
ABEO has been the subject of several recent research reports. HC Wainwright set a $30.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 2nd. Maxim Group set a $35.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 19th. Cantor Fitzgerald set a $36.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 20th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Finally, Zacks Investment Research downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $28.56.
Shares of NASDAQ:ABEO traded down $0.20 during midday trading on Friday, hitting $15.90. 850,422 shares of the company’s stock were exchanged, compared to its average volume of 1,082,414. The company has a market cap of $749.79 million, a PE ratio of -23.94 and a beta of 1.27. Abeona Therapeutics has a 12 month low of $4.55 and a 12 month high of $22.75.
A number of hedge funds have recently modified their holdings of ABEO. Knott David M bought a new stake in Abeona Therapeutics in the 1st quarter worth about $101,000. Virginia Retirement Systems ET AL bought a new stake in Abeona Therapeutics in the 1st quarter worth about $152,000. Teacher Retirement System of Texas bought a new stake in Abeona Therapeutics in the 4th quarter worth about $163,000. Sabby Management LLC bought a new stake in Abeona Therapeutics in the 1st quarter worth about $187,000. Finally, MetLife Investment Advisors LLC bought a new stake in Abeona Therapeutics in the 4th quarter worth about $194,000. 69.11% of the stock is owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.